Indivior Pharmaceuticals, Inc · Pharmaceuticals
$34.83
As of: 2026-09-03 22:34:09 (KST)
+25.5%
Expected return
60%
Success probability
-22.4%
Downside risk
For informational purposes only.
Not investment advice.
Indivior Pharmaceuticals, Inc in the Pharmaceuticals industry carries B grade, driven by a Monte Carlo rating of 74. With an expected return of +25.5% and a 60% chance of positive returns, the stock at $34.83 presents This assessment is based on 10,000 probabilistic scenarios, offering a robust view of the potential return distribution across varying market conditions.
The Reverse DCF analysis places this stock in the "Strong Buy" zone. The implied growth rate (g_implied) of 2.5%, compared with the actual growth rate of 12.2%, reveals the market's pricing assumptions. The P50 intrinsic value sits at $49, offering a reference point against the current price. At $37, the Reverse-DCF implied probability of finishing above $37 stands at 83%.
B grade (score 74): the expected return of +25.5% and 60% positive probability form a middle-ground proposition that warrants monitoring for catalysts.
The Monte Carlo distribution reveals a volatility of 43.4% — elevated, producing a wide dispersion of possible returns. The P50 sits at +19.4%, with a +71.8% gap between P10 (-22.4%) and P75 (+49.4%). the distribution skews positive, indicating upside potential outweighs downside risk
In the worst 5% of scenarios, the 5th percentile value-at-risk is -22.4%. On the operating side, a solid 30.3% operating margin helps cushion downside scenarios. With a volatility of 43.4%, elevated volatility warrants close attention at the current price of $35.
DCF estimates a company's intrinsic value by discounting its future cash flows to present value. Modelvix uses Monte Carlo simulation to analyze thousands of scenarios.
Learn more →WACC is the average rate a company pays to finance its assets, used as the discount rate in DCF analysis. Modelvix simulates how WACC changes affect valuation.
Learn more →Terminal value represents the perpetual value of a business beyond the forecast period, often comprising the majority of DCF value. Modelvix analyzes terminal value uncertainty across growth scenarios.
Learn more →Reverse DCF works backward from the current stock price to infer the growth rate the market expects, helping you assess whether a stock is fairly valued. Modelvix shows what growth assumptions the current price implies.
Learn more →